 LX9211.202 ADPS Results: Separation from Placebo Was Seen by Week 1 in LX9211 Treatment Arm and Continued to Week 6 Weekly Mean Change from Baseline in ADPS to Week 6 LX9211 demonstrated clear evidence of effect, achieving Lexicons goal for the study of supporting advancement in another indication within neuropathic pain Consistent reduction in ADPS ... The post Lexicon Announces Topline Results From Phase 2 Proof-of-Concept Study of LX9211 in Postherpetic Neuralgia appeared first on ForexTV... 